A systematic review of the genetic mechanisms of dolutegravir resistance

SY Rhee, PM Grant, PL Tzou, G Barrow… - Journal of …, 2019 - academic.oup.com
Background Characterizing the mutations selected by the integrase strand transfer inhibitor
(INSTI) dolutegravir and their effects on susceptibility is essential for identifying viruses less …

Persistent low-level viremia in persons living with HIV undertreatment: an unresolved status

C Crespo-Bermejo, ER de Arellano, V Lara-Aguilar… - Virulence, 2021 - Taylor & Francis
Antiretroviral therapy (ART) allows suppressed viremia to reach less than 50 copies/mL in
most treated persons living with HIV (PLWH). However, the existence of PLWH that show …

[HTML][HTML] Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV

NI Paton, J Musaazi, C Kityo, S Walimbwa… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background The World Health Organization recommends dolutegravir with two
nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human …

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy …

M Aboud, R Kaplan, J Lombaard, F Zhang… - The Lancet infectious …, 2019 - thelancet.com
Background Doubts exist regarding optimal second-line treatment options for HIV-1-infected
patients in resource-limited settings. We assessed safety and efficacy of dolutegravir …

[HTML][HTML] Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study

A Gupta-Wright, K Fielding, JJ van Oosterhout… - The Lancet …, 2020 - thelancet.com
Background Antiretroviral therapy (ART) scale-up in sub-Saharan Africa combined with
weak routine virological monitoring has driven increasing HIV drug resistance. We …

Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research

J Dorward, R Lessells, PK Drain, K Naidoo… - The lancet HIV, 2018 - thelancet.com
A new first-line antiretroviral therapy (ART) regimen containing dolutegravir is being rolled
out in low-income and middle-income countries (LMICs). In studies from predominantly high …

[HTML][HTML] Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection …

NI Paton, J Musaazi, C Kityo, S Walimbwa, A Hoppe… - The Lancet …, 2022 - thelancet.com
Background WHO guidelines recommend dolutegravir plus two nucleoside reverse
transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first …

Management of virologic failure and HIV drug resistance

SM McCluskey, MJ Siedner… - Infectious Disease Clinics, 2019 - id.theclinics.com
In 2014, the Joint United Nations Programme on HIV and AIDS established global targets
such that 90% of people with HIV will be diagnosed, 90% of those diagnosed will be on …

[HTML][HTML] Second-line HIV treatment failure in sub-Saharan Africa: A systematic review and meta-analysis

D Edessa, M Sisay, F Asefa - PloS one, 2019 - journals.plos.org
Background Increased second-line antiretroviral therapy (ART) failure rate narrows future
options for HIV/AIDS treatment. It has critical implications in resource-limited settings; …

Effectiveness of protease inhibitor/nucleos (t) ide reverse transcriptase inhibitor–based second-line antiretroviral therapy for the treatment of human immunodeficiency …

AJ Stockdale, MJ Saunders, MA Boyd… - Clinical infectious …, 2018 - academic.oup.com
Abstract Background In sub-Saharan Africa, 25.5 million people are living with human
immunodeficiency virus (HIV), representing 70% of the global total. The need for second-line …